Forbes included Israeli pharmaceutical firm Teva on its ranking of 130 “global superstars.” Ynet reported Monday that the Forbes shortlist, a lead-up to its annual “Global 2,000” ranking, is based on a combination of the firms’ sales, profits, assets and market value. In 2006, Teva registered $8.41 billion in sales, $55 million in profits, $20.47 billion in assets and a market value of $26.91 billion.
JTA has documented Jewish history in real-time for over a century. Keep our journalism strong by joining us in supporting independent, award-winning reporting.
The Archive of the Jewish Telegraphic Agency includes articles published from 1923 to 2008. Archive stories reflect the journalistic standards and practices of the time they were published.
